J Bertrand
Overview
Explore the profile of J Bertrand including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
484
Citations
1725
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goulenok T, Seurat J, Selle A, Jullien V, Leflon-Guibout V, Grall N, et al.
Int J Antimicrob Agents
. 2023 Jun;
62(2):106885.
PMID: 37302771
Objectives: Oral combination of clindamycin and rifampicin is relevant for the treatment of staphylococcal osteoarticular infection (SOAIs). However, rifampicin induces CYP3A4, suggesting a pharmacokinetic interaction with clindamycin with unknown pharmacokinetic/pharmacodynamic...
2.
Paulino M, Espinosa-Bustos C, Bertrand J, Cabezas D, Mella J, Davila B, et al.
SAR QSAR Environ Res
. 2022 Sep;
33(9):701-728.
PMID: 36106834
In this work we have collected a set of 30 trypanosomicidal naphthoquinones and developed pharmacophoric and 3D-QSAR models as tools for the design of new potential anti-Chagasic compounds. Firstly, qualitative...
3.
Meinshausen A, Herbster M, Zwahr C, Soldera M, Muller A, Halle T, et al.
J Appl Microbiol
. 2021 Feb;
131(3):1498-1514.
PMID: 33565669
Aims: Joint infections cause premature implant failure. The avoidance of bacterial colonization of implant materials by modification of the material surface is therefore the focus of current research. In this...
4.
Bollmann M, Pinno K, Ehnold L, Martens N, Martson A, Pap T, et al.
Osteoarthritis Cartilage
. 2020 Nov;
29(2):280-289.
PMID: 33246160
Objective: Osteoarthritis (OA) is a degenerative joint disease inducing the degradation of the articular cartilage. Syndecan-4 (Sdc4) is a heparan sulfate proteoglycan, expressed under inflammatory conditions and by chondrocytes during...
5.
Bertrand J, Boyazis P, Morandini E, Buche M, Benoit A
Rev Med Liege
. 2020 Nov;
75(11):697-698.
PMID: 33155440
Coronary aneurysm has an incidence of 1,1 to 4,9 % in patients undergoing a coronary angiography. Many etiologies may be accused, atherosclerosis is associated in up to 50 % of...
6.
Couffignal C, Bertrand J, Sportiche S, Jarroir M, El Balkhi S, Djebrani-Oussedik N, et al.
Eur J Clin Pharmacol
. 2018 Dec;
75(4):519-528.
PMID: 30554270
Purpose: Lithium (Li), the first-line treatment of bipolar disorder, was first developed as an immediate-release form with a routine therapeutic drug monitoring 12 h after the last dose. In Europe,...
7.
Bertrand J, Delfosse D, Mai V, Awiszus F, Harnisch K, Lohmann C
Bone Joint J
. 2018 Jun;
100-B(7):882-890.
PMID: 29954216
Aims: Early evidence has emerged suggesting that ceramic-on-ceramic articulations induce a different tissue reaction to ceramic-on-polyethylene and metal-on-metal bearings. Therefore, the aim of this study was to investigate the tissue...
8.
Held A, Glas A, Dietrich L, Bollmann M, Brandstadter K, Grossmann T, et al.
Osteoarthritis Cartilage
. 2018 Mar;
26(6):818-823.
PMID: 29559252
Objective: The canonical Wnt signaling pathway has been shown to be involved in regulating chondrocyte hypertrophic differentiation during Osteoarthritis (OA). The aim of this study was to test the therapeutic...
9.
Babazadeh S, Lea S, Kayembe P, Akilimali P, Eitmann L, Anglewicz P, et al.
Health Policy Plan
. 2017 Nov;
33(2):155-162.
PMID: 29136172
Performance Monitoring and Accountability 2020 (PMA2020) is a population-based and facility-based survey program conducted in 11 countries to track contraceptive use dynamics and the supply environment. Annual data collection provides...
10.
Harrach S, Schmidt-Lauber C, Pap T, Pavenstadt H, Schlatter E, Schmidt E, et al.
Blood Cancer J
. 2016 Sep;
6:e470.
PMID: 27635733
Although imatinib is highly effective in the treatment of chronic myeloid leukemia (CML), 25-30% patients do not respond or relapse after initial response. Imatinib uptake into targeted cells is crucial...